Early-Stage to Market Formulations
The company's prowess extends to early-stage formulation development, crucial for First-in-Human (FIH) and Proof-of-Concept (POC) studies, ensuring safety and efficacy profiles align with program objectives. Transitioning seamlessly, our company excels in late-stage and market formulation development, where scalability, stability, and regulatory compliance converge to define success.
Bioavailability Enhancement Technology Development
Our company's commitment to innovation shines through its expertise in bioavailability enhancement technologies. Leveraging cutting-edge methodologies such as micronization and spray drying, our company optimizes drug absorption, particularly for poorly soluble APIs. These advancements not only enhance therapeutic efficacy but also streamline manufacturing processes, driving overall efficiency.
Release Formulations and Pediatric Solutions
Our company's portfolio encompasses a spectrum of dosage forms, including tablets, capsules, solutions, and suspensions. Our company specializes in developing immediate and modified-release formulations, tailoring drug release kinetics to meet specific therapeutic needs.
Moreover, our pediatric development solutions address critical dosage and administration requirements for the vulnerable pediatric population, ensuring safe and effective treatments.